Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 May;36(6):1219-26.
doi: 10.1038/npp.2011.6. Epub 2011 Feb 9.

Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients

Affiliations
Free PMC article
Randomized Controlled Trial

Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients

Mateus M Bergamaschi et al. Neuropsychopharmacology. .
Free PMC article

Abstract

Generalized Social Anxiety Disorder (SAD) is one of the most common anxiety conditions with impairment in social life. Cannabidiol (CBD), one major non-psychotomimetic compound of the cannabis sativa plant, has shown anxiolytic effects both in humans and in animals. This preliminary study aimed to compare the effects of a simulation public speaking test (SPST) on healthy control (HC) patients and treatment-naïve SAD patients who received a single dose of CBD or placebo. A total of 24 never-treated patients with SAD were allocated to receive either CBD (600 mg; n=12) or placebo (placebo; n=12) in a double-blind randomized design 1 h and a half before the test. The same number of HC (n=12) performed the SPST without receiving any medication. Each volunteer participated in only one experimental session in a double-blind procedure. Subjective ratings on the Visual Analogue Mood Scale (VAMS) and Negative Self-Statement scale (SSPS-N) and physiological measures (blood pressure, heart rate, and skin conductance) were measured at six different time points during the SPST. The results were submitted to a repeated-measures analysis of variance. Pretreatment with CBD significantly reduced anxiety, cognitive impairment and discomfort in their speech performance, and significantly decreased alert in their anticipatory speech. The placebo group presented higher anxiety, cognitive impairment, discomfort, and alert levels when compared with the control group as assessed with the VAMS. The SSPS-N scores evidenced significant increases during the testing of placebo group that was almost abolished in the CBD group. No significant differences were observed between CBD and HC in SSPS-N scores or in the cognitive impairment, discomfort, and alert factors of VAMS. The increase in anxiety induced by the SPST on subjects with SAD was reduced with the use of CBD, resulting in a similar response as the HC.

Figures

Figure 1
Figure 1
Changes in Visual Analogue Mood Scale (VAMS) factors induced by simulated public speaking test (SPST), measured in 12 social anxiety patients who received cannabidiol (formula image), 12 social anxiety patients who received placebo (formula image) and 12 healthy controls (formula image). The phases of the experimental session are: b, basal; P, pretest; a, anticipation; S, speech performance; F1, post-speech measures 1; F2, post-speech measures 2. Points in the curves indicate mean and vertical bars SEM. *Indicates significant differences from healthy control and + from social anxiety patients who received cannabidiol.
Figure 2
Figure 2
Changes in SSPS-N scores induced by simulated public speaking test (SPST). Other specifications are in the legend of Figure 1. *Indicates significant differences from healthy control and + from social anxiety patients who received cannabidiol.

Similar articles

See all similar articles

Cited by 122 articles

See all "Cited by" articles

Publication types

MeSH terms

Feedback